Nanoscope Therapeutics Announces Presentation at the 2020 AAO
Nanoscope Therapeutics, which is developing ocular gene therapy based on its proprietary ambient light activatable MCO Optogenetic Technology Platform, announced that an oral presentation at the Late Breaking Developments session of Retina Subspecialty Day will be made during the American Academy Ophthalmology (AAO) 2020 Annual Meeting, taking place November 13-15, 2020.
The presentation will feature data from the vMCO-010 phase 1/2a intravitreal trial for the treatment of retinitis pigmentosa (RP). Details are as follows:
Title: Phase 1/2a Study of Intravitreal Optogenetics Gene Therapy for Vision Restoration in Advanced Retinitis Pigmentosa
Presenter: Dr. Santosh Mahapatra, Chief Medical Officer, JPM Rotary Eye Hospital and Research Center
Date/time: 13thNovember 2020, 3.00 PM PST; also available on-demand
Session title: Late Breaking Developments, Part I
The Nanoscope co-authors of the presentation are Sai Chavala (Chief Medical Officer), Samuel Barone (Advisor), Samarendra Mohanty (President and Chief Technology & Innovation Officer), Subrata Batabyal, Michael Carlson, Ananta Ayyagari, and Kissaou Tchedre.